In patients with melanoma, addition of an experimental gp100 peptide/IFA vaccine to IL-2 gave a higher clinical response rate than observed in patients receiving IL-2 alone, and also higher than previously observed for gp100 peptide vaccine alone, suggesting IL-2 can also function as a vaccine adjuvant in humans [89]. This evidence concerns the gene PMEL and melanoma.